Inhibitors of mTOR

Heinz Josef Klümpen*, Jos H. Beijnen, Howard Gurney, Jan H M Schellens

*Corresponding author for this work

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances.

Original languageEnglish
Pages (from-to)1262-1269
Number of pages8
JournalOncologist
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2010
Externally publishedYes

Fingerprint Dive into the research topics of 'Inhibitors of mTOR'. Together they form a unique fingerprint.

  • Cite this

    Klümpen, H. J., Beijnen, J. H., Gurney, H., & Schellens, J. H. M. (2010). Inhibitors of mTOR. Oncologist, 15(12), 1262-1269. https://doi.org/10.1634/theoncologist.2010-0196